Results 121 to 130 of about 1,715,615 (239)
Germline loss-of-function mutations in BRCA1 and BRCA2 (BRCA) genes are well-established as causative factors for hereditary breast and ovarian cancer (HBOC), conferring an approximately tenfold increased lifetime risk.
Qianqian Shi +12 more
doaj +1 more source
ABSTRACT Fanconi Anemia (FA) is the most frequent inherited bone marrow failure syndrome. A role for the XRCC2 gene in FA was suspected in 2012 and confirmed in 2016, but only two affected individuals have been described thus far, and no long‐term follow‐up is available.
Sabina Cenciarelli +11 more
wiley +1 more source
Footnote. t: moderated t-statistic for 66 genes that best discriminate between BRCA2 and BRCAX tumors. p: p-value after Benjamini Hochberg correction (all genes had an unadjusted p-value
Françoise Bonnet (292500) +13 more
core +1 more source
CCNE1: A Cell Cycle Regulator That Influences Tumor Progression
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Liang Yan +6 more
wiley +1 more source
ABSTRACT Background Gallbladder cancer (GBC) is a biologically complex malignancy arising from the epithelial lining of the gallbladder, with adenocarcinoma constituting the major histological subtype. Early detection is challenging because of vague clinical manifestations and the organ's deep‐seated anatomical location, resulting in diagnosis at ...
Nisha Manav +4 more
wiley +1 more source
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Population testing for cancer predisposing BRCA1/BRCA2 mutations [PDF]
Background: Technological advances raise the possibility of systematic population-based genetic testing for cancer-predisposing mutations, but it is uncertain whether benefits outweigh disadvantages.
Wardle, J
core
Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers
BRCA1 and BRCA2 pathogenic germline variant (PGV) carriers may be at increased risk of gastric cancer (GC), especially in the case of prior or active Helicobacter pylori (Hp) infection. The extent to which Hp influences BRCA1 and BRCA2‐associated GC remains uncertain. Here, the authors evaluated plasma samples from a U.S. cohort of BRCA1, BRCA2, PALB2,
Kole H. Buckley +12 more
wiley +1 more source
BRCA1 and BRCA2mutations in breast cancer patients from Venezuela
A sample of 58 familial breast cancer patients from Venezuela were screened for germline mutations in the coding sequences and exon-intron boundaries of BRCA1 (MIM no. 113705) and BRCA2 (MIM no.
Karlena Lara +3 more
doaj
ABSTRACT Introduction The UK National Institute for Health and Care Excellence (NICE) produce guidelines that provide evidence‐based recommendations to support clinical care across England and Wales, but remain available in unstructured natural language form.
Ashvin Gupta +3 more
wiley +1 more source

